Myriad Genetics Inc (MYGN)

Return on assets (ROA)

Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Net income (ttm) US$ in thousands -155,200 -234,600 -263,300 -274,400 -248,200 -146,200 -112,000 -77,300 -17,600 -8,200 -27,200 -34,800 -114,800 -225,300 -194,100 -199,500 -148,300 -26,200 -15,300 4,600
Total assets US$ in thousands 1,085,100 1,110,500 1,146,500 1,149,100 1,187,200 1,169,300 1,198,700 1,212,000 1,210,200 1,255,400 1,320,700 1,335,900 1,360,300 1,336,900 1,444,500 1,404,600 1,446,700 1,578,300 1,591,200 1,562,700
ROA -14.30% -21.13% -22.97% -23.88% -20.91% -12.50% -9.34% -6.38% -1.45% -0.65% -2.06% -2.60% -8.44% -16.85% -13.44% -14.20% -10.25% -1.66% -0.96% 0.29%

June 30, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $-155,200K ÷ $1,085,100K
= -14.30%

The return on assets (ROA) for Myriad Genetics Inc has been fluctuating over the past few quarters, ranging from negative figures to slightly positive.

The company experienced negative ROA values from September 2019 to June 2022, indicating that its net income generated from its assets was insufficient to cover the total assets employed. During this period, the ROA deteriorated, reaching its lowest point of -23.88% in September 2023.

However, starting from December 2022, there was a gradual improvement in ROA, with the ratio moving towards less negative values and even turning slightly positive in some periods. This upward trend continued until March 2024, with the ROA standing at -0.65%.

Overall, while Myriad Genetics Inc has faced challenges in generating returns from its assets in the past, the recent positive trend suggests potential improvements in the company's asset utilization and profitability.


Peer comparison

Jun 30, 2024